Multiple Myeloma Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
11-0685 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma
11506A Collection of Bone Marrow Samples from Patients with Multiple Myeloma who Already are Undergoing a Bone Marrow Biopsy and Aspirate
Select
14541B Phase 1 Clinical Trial of NPI-0052 in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
10-064-B Molecular characterization of hematopoietic malignancies
Select
10-551-B Pilot study T cell depletion in the setting of autologous stem cell transplantation for patients with multiple myeloma
11-0445 A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Select
12-0078 A Phase I Study of the Combination of Panobinostat and Carfilzomib for Patients with Relapsed and Refractory Multiple Myeloma
Select
12-1088 Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma
Select
12-1466 A Phase 3, Randomized, Controlled, Open- label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Select
12-1725 Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment with Carfilzomib, Lenalidomide and Low dose Dexamethasone (CRd) in Transplant Candidates with Newly Diagnosed, Multiple Myeloma (MM) Requiring Systemic Chemotherapy
Select
12-1907 A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma
Select
12-2150 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients with Hematologic Malignancies

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.